Dendritic cells: therapeutic potentials.
Dendritic cells (DCs) are leukocytes that are specialized to capture antigens and initiate T-cell-mediated immune responses. After capture of antigens, DCs, then in an immature stage, leave their tissue of residence and migrate through the lymph/blood into secondary lymphoid organs where they differentiate into mature cells. Because DCs can prime animals in the absence of any other adjuvant, they have been termed 'nature's adjuvant'. Large numbers of DCs can now be generated from circulating monocytes or from CD34 hematopoietic progenitors in response to GM-CSF in combination with either IL4 or TNF alpha. In mice, tumor antigen loaded DCs have been shown to prevent the development of tumors and even to induce the regression of established tumors. DCs therapy represents a very promising approach to the treatment of cancer and infectious diseases. Early studies indicate the existence of DC populations that can induce tolerance and may prove useful in organ transplantation.
Banchereau
J
J
Schering-Plough, Laboratory for Immunological Research, Dardilly, France.
D000818:Animals; D002469:Cell Separation; D064987:Cell- and Tissue-Based Therapy; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation*; D006801:Humans; D007108:Immune Tolerance; D051379:Mice; D016377:Organ Transplantation